LCB43 / LigaChem Biosci - LARVOL DELTA

Preclinical Evaluation of ?-Glucuronide Linker-Based BCMA Adcs with MMAF, Propbd, and TOP1 Inhibitor Payloads Support Differentiated Clinical Development Strategies (IMS 2026) - "Introduction: Belantamab mafodotin combination therapies have demonstrated the potential of BCMA-targeted antibody-drug conjugates (ADCs) in the multiple myeloma treatment landscape, yet are limited by the prevalence of ocular toxicity. LCB14-2524 (LBG-MMAF), LCB14-2516 (LBG-proPBD), and LCB43-101001 (Novel TOP1i) all demonstrated preclinical profiles supporting further development. LCB14-2524 has been prioritized for first clinical assessment based on the combination of pre-clinical profile and clinical experience with the platform linker-payload (FS-1502/IKS014). LCB14-2516 or LCB43-101001 provide differentiated follow-on opportunities to introduce new payload mechanism into the multiple myeloma treatment landscape."

Preclinical • Hematological Malignancies • Multiple Myeloma • Ophthalmology • TOP1